EMA Priority Medicines scheme (PRIME): will more paying-for-performance agreements be needed due to immature data?

14 September 2018 - The EU’s centralized procedure for the authorization of a new drug is performed by the EMA.  ...

Read more →

Conditional marketing authorisations give patients access to important new medicines earlier

23 January 2017 - EMA publishes report with data collected between 2006 and June 2016. ...

Read more →

Give and take: US pharma & payers forge risk-sharing deals for new heart drugs

1 November 2016 - U.S. commercial payers and pharmaceutical companies have rarely engaged in outcomes-based risk-sharing arrangements, at least until ...

Read more →